Immatics, Compass Therapeutics and Incyte each announced ESMO Congress 2026 presentations, spanning PRAME immunotherapy, tovecimig and four rapid oral sessions focused broadly on difficult-to-treat cancers.
Immatics said it will present data across its PRAME cancer immunotherapy franchise at ESMO Congress 2026. Separately, Compass Therapeutics said tovecimig data was accepted for an oral presentation, while Incyte said its data will be featured in four rapid oral presentations tied broadly to improving outcomes in difficult-to-treat cancers. The announcements provide limited study-level detail but point to ESMO Congress 2026 as a key venue for upcoming oncology pipeline updates.